Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran Prioritized Therapy and ASCVD Risk Progression in Chinese Moderate- to High-Risk Primary Prevention Patients
ChiCTR2500107520Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of inclisiran in hypercholesterolemia, hyperlipidemia and atherosclerotic disease (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: ASCVD risk level evolution. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiahyperlipidemiaatherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2500107520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107520.